Abstract: The present invention provides combined use of a carnosinase inhibitor with L-carnosine and its related substance, and a composition containing the same, which are useful for treatment or prevention of various diseases, improvement of health conditions, improvement of exercise ability, improvement of skin health, prevention of the side effects of alcohol drinking and the like in mammals including human.

Abstract: The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides combined use of a carnosinase inhibitor with L-carnosine and its related substance, and a composition containing the same, which are useful for treatment or prevention of various diseases, improvement of health conditions, improvement of exercise ability, improvement of skin health, prevention of the side effects of alcohol drinking and the like in mammals including human.

Abstract: A quinoline derivative of the formula (I): ##STR1## wherein each phenyl ring of A and B can have one or more substituents; X is ##STR2## (R.sup.1 is a hydrogen atom, a lower alkyl group or a lower alkoxy group) or ##STR3## (R.sup.2 is a hydrogen atom or a lower alkyl group); Y is --(CH.sub.2).sub.m --(m is 0, 1 or 2) or --CH.dbd.CH--, Z is a group of the formula: ##STR4## wherein each phenyl ring of C and D can have one or more substituents, R.sup.3 and R.sup.4 are each a hydrogen or halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.5 is a halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.6 and R.sup.7 are each a hydrogen atom or a lower alkyl group, and n, o and p are each 1 or 2; l is 0 or 1; or its salt, which is useful as a drug for atherosclerosis.

Abstract: Novel heterocyclic compound of the general formula: ##STR1## wherein ring A and ring B each means a benzene ring which is substituted or unsubstituted; X means a group of the formula: ##STR2## wherein R.sup.2 is hydrogen an alkyl or an alkoxy; m is 0 or 1, the formula: ##STR3## wherein R.sup.3 is hydrogen or an alkyl, or the formula: --O--CO--; Y means a bond, --NH--, an C.sub.1 or 2 alkylene group or --CH.dbd.CH--; R.sup.1 means a hydrocarbon group which is substituted or unsubstituted; and n means a whole number of 3 through 6, or a salt thereof, having excellent acyl-CoA:cholesterol acyltransferase inhibitory activity, and a method for preparing it and its use.

Abstract: A quinoline derivative of the formula (I): ##STR1## wherein each phenyl ring of A and B can have one or more substituents; X is ##STR2## (R.sup.1 is a hydrogen atom, a lower alkyl group or a lower alkoxy group) or ##STR3## (R.sup.2 is a hydrogen atom or a lower alkyl group); Y is --(CH.sub.2).sub.m --(m is 0, 1 or 2) or --CH.dbd.CH--, Z is a group of the formula: ##STR4## wherein each phenyl ring of C and D can have one or more substituents, R.sup.3 and R.sup.4 are each a hydrogen or halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.5 is a halogen atom, or a lower alkyl, lower alkoxy, lower acyloxy, lower alkoxycarbonyloxy, N,N-di-lower alkylcarbamoyloxy, optionally esterified carboxy or hydroxyl group, R.sup.6 and R.sup.7 are each a hydrogen atom or a lower alkyl group, and n, o and p are each 1 or 2; l is 0 or 1; or its salt, which is useful as a drug for atherosclerosis.

Abstract: A chromene derivative of the formula (I) ##STR1## wherein each ring of A and B can have one or more substituents; X is an oxygen atom or sulfur atom, Y is an oxygen or sulfur atom or H.sub.2, Z is a bond, --NH-- or a saturated or unsaturated lower alkylene group and R is a hydrocarbon radical which is unsubstituted or substituted, or its salt, which is useful as a drug for atherosclerosis.

Abstract: Novel heterocyclic compound of the general formula: ##STR1## wherein ring A and ring B each means a benzene ring which is substituted or unsubstituted; X means a group of the formula: ##STR2## wherein R.sup.2 is hydrogen, an alkyl or an alkoxy; m is 0 or 1, the formula: ##STR3## wherein R.sup.3 is hydrogen or an alkyl, or the formula: --O--CO--; Y means a bond, --NH--, an C.sub.1 or 2 alkylene group or --CH.dbd.CH--; R.sup.1 means a hydrocarbon group which is substituted or unsubstituted; and n means a whole number of 3 through 6, or a salt thereof, having excellent acyl-CoA:cholesterol acyltransferase inhibitory activity, and a method for preparing it and its use.

Abstract: Thienopyridine derivatives of the formula (I): ##STR1## wherein the ring A is an optionally substituted benzene ring; the ring B is an optionally substituted thiophene ring: X is a group of the formula: ##STR2## (wherein R.sup.1 is hydrogen, alkyl or alkoxy; and n is 0 or 1) or a group of the formula: ##STR3## (wherein R.sup.2 is hydrogen or alkyl); Y is a single bond, --NH--, alkylene having 1 or 2 carbon atoms or --CH.dbd.CH--; and R.sup.3 is an optionally substituted hydrocarbon group, or their salts are disclosed. They show strong ACAT inhibitory activities.

Abstract: Quinoline derivatives of the formula: ##STR1## , wherein R is hydrogen, alkyl or aralkyl; m and n are 0 or 1, and each of rings A, B and C can have substituents, which are useful as inhibitors for acyl-CoA:Cholesterolacyltransferase.

Abstract: A quinoline derivative of the formula (I): ##STR1## wherein each phenyl ring of A, B and C can have one or more substituents, X is ##STR2## (R.sup.1 is a hydrogen atom or a lower alkyl group) or ##STR3## (R.sup.2 is a lower alkyl group or a lower alkoxy group), and n is 0 or 1, or its salt, which possesses an inhibitory action against acyl-CoA: cholesterol acyltransferase.

Abstract: Thienopyridine derivatives of the formula (I): ##STR1## wherein the ring A is an optionally substituted benzene ring; the ring B is an optionally substituted thiophene ring: X is a group of the formula: ##STR2## (wherein R.sup.1 is hydrogen, alkyl or alkoxy; and n is 0 or 1) or a group of the formula: ##STR3## (wherein R.sup.2 is hydrogen or alkyl); Y is a single bond, --NH--, alkylene having 1 or 2 carbon atoms or --CH.dbd.CH--; and R.sup.3 is an optionally substituted hydrocarbon group, or their salts are disclosed. They show strong ACAT inhibitory activities.

Abstract: A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has the meaning given above) with a halogenating agent or sulfonyl halide to give a compound of the formula: ##STR3## (wherein R.sup.1 has the meaning given above and X is a halogen or an alkyl- or aryl-sulfonyloxy), (2) reacting the resulting compound with a compound of the formula: ##STR4## to give a compound of the formula: ##STR5## (wherein R.sup.1 has the meaning given above), (3) reacting the resulting compound with a compound of the formula: ##STR6## to give a compound of the formula: ##STR7## (wherein R.sup.1 has the meaning given above), and (4) subjecting the resulting compound to catalytic reduction.

Abstract: Dihydropyridine derivatives and acid addition salts thereof which are of use as prophylactic or/and therapeutic drugs for cardiovascular diseases, said dihydropyridine derivatives having the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are the same or different and each is alkyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; R.sup.4 and R.sup.5 are the same or different and each is hydrogen, halogen, nitro, trifluoromethyl, alkyl, cycloalkyl, alkoxy, cyano, alkoxycarbonyl or alkylthio; R.sup.6 is hydrogen, alkyl, cycloalkyl, aralkyl, aryl or a pyridyl; X is oxygen, sulfur, vinylene, azomethine or a group of the formula ##STR2## A is alkylene; Ar is aryl or a pyridyl; m is an integer of 1 to 3; n is an integer of 0 to 2.

Abstract: A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has a meaning given above) with a halogenating agent or sulfonyl halide to give a compound of the formula: ##STR3## (wherein R.sup.1 has a meaning given above and X is a halogen or an alkyl- or aryl-sulfonyloxy), (2) reacting the resulting compound with a compound of the formula: ##STR4## to give a compound of the formula: (wherein R.sup.1 has the meaning given above), (3) reacting the resulting compound with a compound of the formula: ##STR5## to give a compound of the formula: ##STR6## (wherein R.sup.1 has the meaning given above), and (4) subjecting the resulting compound to catalytic reduction.

Abstract: 1,4-Benzoxazine derivatives representable by the general formula; ##STR1## wherein R.sup.1 and R.sup.2 independently stand for hydrogen, halogen atom, nitro group, an optionally substituted lower alkyl group, an optionally substituted amino group, an optionally substituted hydroxyl group, a lower alkoxycarbonyl group, or when R.sup.1 and R.sup.2 are adjacent to each other,R.sup.1 and R.sup.2 combinedly stand for a ring representable by --CH.sub.2).sub.m (wherein m denotes an integer of 3 to 5) or --O--CH.sub.2).sub.n O-- (wherein n denotes an integer of 1 to 3),R.sup.3 stands for hydrogen or a lower alkyl group,R.sup.4 and R.sup.5 independently stand for hydrogen, halogen atom, an optionally substituted lower alkyl group or an optionally substituted hydroxyl group, andA stands for an alkylene groupor acid addition salts thereof, are useful as prophylactic or therapeutic drugs for, among others, hypertension or ischemic dieases.

Abstract: A thiazolidinedione derivative of the general formula: ##STR1## wherein X is an oxygen or sulfur atom, R.sup.1 and R.sup.2 each independently is hydrogen or a hydrocarbon residue which may optionally be substituted and R.sup.1 and R.sup.2 may jointly, together with the oxazole or thiazole ring, form a condensed ring and A is a lower alkylene group; or a salt thereof, are novel compounds, which exhibit in mammals blood sugar- and lipid-lowering activity, and are of value as a therapeutic agent for diabetes and/or therapeutic agent for hyperlipemia.

Abstract: Compounds of the general formula: ##STR1## wherein, R.sup.1 and R.sup.2 are, the same or different, hydrogen, a halogen, a lower alkyl, a cycloalkyl, a lower alkoxy, trifluoromethyl or a phenylalkyloxy whose phenyl ring may be substituted by one to three substituents selected from the group consisting of a halogen, a lower alkyl, a lower alkoxy, methylenedioxy and trifluoromethyl; R.sup.3 is hydrogen or methyl; R.sup.4 is carboxyl or an esterified carboxyl; and X is oxygen or sulfur, or a salt thereof. These compounds possess aldose reductase inhibitory and platelet aggregation inhibitory activities, and are of use as drugs for prevention and treatment of diabetic complications such as diabetic cataract, retinophathy, nephropathy, and neuropathy.

Abstract: A compound of the formula: ##STR1## (wherein R.sup.1 is hydrogen or a lower alkyl) can be produced advantageously by (1) reacting a compound of the formula: ##STR2## (wherein R.sup.1 has the meaning given above) with a halogenating agent or sulfonyl halide to give a compound of the formula: ##STR3## (wherein R.sup.1 has the meaning given above and X is a halogen or an alkyl- or aryl-sulfonyloxy), (2) reacting the resulting compound with a compound of the formula: ##STR4## to give a compound of the formula: ##STR5## (wherein R.sup.1 has the meaning given above), (3) reacting the resulting compound with a compound of the formula: ##STR6## to give a compound of the formula: ##STR7## (wherein R.sup.1 has the meaning given above), and (4) subjecting the resulting compound to catalytic reduction.